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In June 2005, a World Health Organization (WHO)-
International Programme on Chemical Safety expert meeting was
held inGeneva duringwhich the toxic equivalency factors (TEFs) for
dioxin-like compounds, including some polychlorinated biphenyls
(PCBs), were reevaluated. For this reevaluation process, the refined
TEF database recently published by Haws et al. (2006, Toxicol. Sci.
89, 4–30) was used as a starting point. Decisions about a TEF value
were made based on a combination of unweighted relative effect
potency (REP) distributions from this database, expert judgment,
and point estimates. Previous TEFs were assigned in increments of
0.01, 0.05, 0.1, etc., but for this reevaluation, it was decided to use half
order ofmagnitude increments on a logarithmic scale of 0.03, 0.1, 0.3,
etc. Changes were decided by the expert panel for 2,3,4,7,8-penta-
chlorodibenzofuran (PeCDF) (TEF ¼ 0.3), 1,2,3,7,8-pentachlorodi-
benzofuran (PeCDF) (TEF¼ 0.03), octachlorodibenzo-p-dioxin and
octachlorodibenzofuran (TEFs¼ 0.0003), 3,4,4#,5-tetrachlorbiphen-
yl (PCB81) (TEF¼ 0.0003), 3,3#,4,4#,5,5#-hexachlorobiphenyl (PCB
169) (TEF ¼ 0.03), and a single TEF value (0.00003) for all relevant
mono-ortho–substituted PCBs. Additivity, an important prerequisite
of theTEFconceptwas again confirmedby results fromrecent in vivo
mixture studies. Someexperimental evidence shows that non-dioxin–
like aryl hydrocarbon receptor agonists/antagonists are able to
impact the overall toxic potency of 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD) and related compounds, and this needs to be in-
vestigated further. Certain individual and groups of compoundswere
identified for possible future inclusion in the TEF concept, including
3,4,4#-TCB (PCB 37), polybrominated dibenzo-p-dioxins and diben-
zofurans, mixed polyhalogenated dibenzo-p-dioxins and dibenzofur-
ans, polyhalogenated naphthalenes, and polybrominated biphenyls.
Concern was expressed about direct application of the TEF/total
toxic equivalency (TEQ) approach to abiotic matrices, such as soil,
sediment, etc., for direct application in human risk assessment. This
is problematic as the present TEF scheme andTEQmethodology are
primarily intended for estimating exposure and risks via oral inges-
tion (e.g., by dietary intake). A number of future approaches to
determine alternative or additional TEFs were also identified. These
included the use of a probabilistic methodology to determine TEFs
that better describe the associated levels of uncertainty and ‘‘sys-
temic’’ TEFs for blood and adipose tissue and TEQ for body burden.
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Polychlorinated dibenzo-p-dioxins (PCDDs), polychlori-
nated dibenzofurans (PCDFs), and polychlorinated biphenyls
(PCBs) are persistent organic pollutants that are omnipresent in
the global environment. Many of these hydrophobic and
lipophilic compounds are highly resistant to metabolism in
vertebrate species, including humans. As a result of these
properties, biomagnification occurs through the food chain, and
high tissue concentrations can often occur in top predator
species. Most, if not all, toxic and biological effects of these
compounds are mediated through the aryl hydrocarbon re-
ceptor (AhR), a cytosolic receptor protein present in most
vertebrate tissues with high affinity for 2,3,7,8–substituted
PCDD/Fs and some non-ortho–substituted PCBs (Poland et al.,
1985; Safe, 1986; Safe et al., 1985). Hundreds of congeners are
formed during synthetic processes such as combustion and
certain industrial activities (Hutzinger et al., 1985). Thus,
human exposure either through food or the environment results
in the uptake of a large number of these compounds. As
a result, humans retain dozens of PCB congeners in their
tissues, blood, and milk (Liem et al., 2000; Schecter et al.,
1994). Most PCDD and PCDF congeners with a 2,3,7,8-
chlorine substitution pattern are also strongly retained (Van den
Berg et al., 1994). Thus, risk assessment of these compounds
involves a complex mixture of PCDD, PCDF, and PCB
compounds that are AhR agonists sharing a common mecha-
nism of action and should not be done for only one specific
congener.
During the last few decades, data from many experimental
studies with mixtures of these compounds are consistent with
an additive model, although deviations up to a factor of two,
and sometimes more, from additivity are not uncommon
(Barnes, 1991; Barnes et al., 1991; Birnbaum and DeVito,
1995; Safe, 1986, 1997, 1998; Safe et al., 1985; Van den Berg
et al., 1998; Zabel et al., 1995). As a result of this generally
accepted additivity, the toxic equivalency concept was de-
veloped during the mid 1980’s (Barnes, 1991; Barnes et al.,
1991; Safe, 1986; Safe et al., 1985). It uses the relative
effect potency (REP) determined for individual PCDD, PCDF,
and PCB compounds for producing toxic or biological
effects relative to a reference compound, usually 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). The total toxic equiva-
lent (TEQ) is operationally defined by the sum of the products
of the concentration of each compound multiplied by its TEF
value and is an estimate of the total 2,3,7,8-TCDD–like activity
of the mixture.
Since the early 1990’s, the World Health Organization
(WHO) has organized expert meetings with the objective to
harmonize the toxic equivalency factors (TEFs) for dioxin and
dioxin-like compounds on the international level, thereby
giving recommendations to national regulatory authorities.
Prior to 2005, two WHO (re)evaluations of the TEFs were
conducted. In 1993, the first evaluation was done that resulted
in human and mammalian WHO TEFs for all 2,3,7,8-PCDDs
and PCDFs but also a recommended TEF value for several
PCBs (Ahlborg et al., 1994). A WHO TEF (re)evaluation was
again done in 1997, which led to the revision of several
mammalian TEF values of important congeners and with-
drawal of the di-ortho PCBs from the TEF concept for dioxin-
like compounds. In addition, the first WHO TEF values for
birds and fish were proposed during this meeting (Van den Berg
et al., 1998). To support this meeting, the Karolinska Institutet
in Stockholm (Sweden) prepared a database with results from
all studies for which REP values were known at that time,
and they were used to determine the WHO 1998 TEF values.
This REP database was recently used as a starting point to
compile a much more extensive database for REP values (Haws
et al., 2006). In June 2005, a third WHO expert meeting to
reevaluate current mammalian TEF values was held in Geneva,
Switzerland. Preceding this meeting, a 1-day public hearing
took place with stakeholders, interested parties, and members
of the expert panel, during which the panel members were able
to discuss various aspects of the TEF and TEQ concept with the
participants and use this information during the actual re-
evaluation process. Besides the reevaluation of the WHO 1998
TEF values, the validity, criteria and correct use of the TEF/
TEQ concept, and methods for proper identification of TEF
values and possible compounds for future inclusion were dis-
cussed. This report presents the results of this meeting, includ-
ing the TEF values that now are proposed as WHO 2005 TEFs
for human risk assessment of these compounds.
VALIDITY AND CRITERIA OF THE TEF CONCEPT
During the 2005 WHO reevaluation of the 1998 WHO TEF
values, both the general TEF concept and REP criteria were
extensively discussed. The criteria for inclusion of a compound
in the TEF concept at this meeting were similar to those used at
the two earlier WHO expert meetings (Ahlborg et al., 1994;
Van den Berg et al., 1998). These criteria are that for inclusion
in the TEF concept a compound must
 show a structural relationship to the PCDDs and PCDFs;
 bind to the AhR;
 elicit AhR-mediated biochemical and toxic responses;
 be persistent and accumulate in the food chain.
It was recognized that the vast amount of literature available in
this field provides many examples of uncertainties associated
with the determination of REPs. In addition, high variation can
sometimes be found in REP values for the same congener and
for similar endpoints in different species (e.g., rats vs. mice).
The 2005 WHO reevaluation of the TEF values made
extensive use of the review and REP database of Haws et al.
(2006) in which a set of criteria was developed to identify,
include, or exclude REPs for dioxin-like compounds. Extensive
consultations between the compilers of this database with the
WHO represented by M. van den Berg and R. E. Peterson took
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place. However, it must be emphasized that for this 2005 TEF
reevaluation, the expert panel used all available REPs, either
included or excluded in this database, and made their own
assessment (Haws et al., 2006). Studies published since the
1997 reevaluation were also fully evaluated.
When reviewing the database of mammalian REPs for
dioxin-like compounds, it was observed that even for the most
thoroughly studied congeners like 2,3,4,7,8-pentachlorodiben-
zofuran (PeCDF) and PCB 126, significant gaps in knowledge
exist (Haws et al., 2006). Reasons for significant differences in
REPs for the same congener can be caused by the use of
different dosing regimens (acute vs. subchronic), different
endpoints, species, and mechanisms (e.g., tumor promotion
caused by at least two different mechanisms as for mono-
ortho–substituted PCBs), as well as different methods used for
calculating REPs. Thus, different methodological approaches
used in different studies clearly provide uncertainties when
deriving and comparing REPs. If future study designs to derive
REPs were more standardized and similar, the variation in
REPs when using the same congener, endpoint, and species
might be expected to be smaller.
At this 2005 meeting, the ‘‘ideal’’ REP study design was
discussed as previous WHO TEF evaluations did not provide
sufficient information regarding the criteria that needed to be
met to establish an REP value and give an expert panel the
greatest degree of confidence in a particular REP. The
following general guidelines for a future ideal dose-response
study used to determine an in vivo REP resulted from the
workshop:
 A full dose-response curve for both the congener and for
2,3,7,8-TCDD should be determined.
 The congener and 2,3,7,8-TCDD should be administered
by the same route to animals of the same species, strain, sex,
and age, and the animals should be housed, fed the same diet,
and maintained under the same conditions in the same
laboratory.
 Ideally, the absolute maximal response (efficacy) should
be similar for both the congener and for 2,3,7,8-TCDD and
their dose-response curves should be parallel, but in practice,
this is often not observed for various reasons.
 If the above dose-response criteria are met, the REP
should be calculated by dividing the effective dose 50%
(ED50) of 2,3,7,8-TCDD by the ED50 of the congener.
 If full dose-response relationships are not attained and
determination of ED50’s is not possible, lowest observed effect
doses or concentrations or benchmark doses could be used to
determine the REP. However, such an REP has more un-
certainty than if ED50’s were used.
For studies that are designed to determine REPs, it is clear that
in vivo studies have the highest priority because they combine
both toxicokinetic as well as toxicodynamic aspects. Therefore,
in vivo studies should preferably be used for setting TEFs.
Nevertheless, in vitro studies can contribute significantly to
establish the AhR-mediated mechanism of action of a com-
pound and explain possible differences in species sensitivity,
especially with respect to that of humans versus experimental
animal species. For in vitro studies, stricter criteria should be
applied as these are from an experimental design point of view
usually easier to accommodate than in vivo studies. For in vitro
studies, the following experimental design is suggested to
determine an REP:
 Avehicle group and at least four graded concentrations of
a congener and four graded concentrations of 2,3,7,8-TCDD
should be selected.
 For congener and 2,3,7,8-TCDD treatment groups, three
of these concentrations should elicit a response that falls
between the EC20 and EC80 for the congener and for 2,3,7,8-
TCDD.
 At least one concentration should elicit a maximal
response (EC100), and the concentration-response curves
should be parallel.
 The REP should be based on the EC50 of 2,3,7,8-TCDD
and the EC50 of the congener.
In general, 2,3,7,8-TCDD has been used as the reference
compound of choice, but in several studies, PCB 126 has been
used instead of 2,3,7,8-TCDD. Based on available data from
the literature, it was concluded that PCB 126 could indeed be
used as a reference compound in rat studies with an REP value
of 0.1. Recent studies have confirmed this value for multiple
endpoints (Toyoshiba et al., 2004; Walker et al., 2005).
However, it should be examined in more detail if the same
REP for PCB 126 is applicable as a reference compound for
mouse studies. The REP values for some endpoints such as
enzyme induction tend to be significantly lower in mice than in
rats (Birnbaum and DeVito, 1995; DeVito et al., 2000; Harper
et al., 1993; van Birgelen et al., 1996a). In this respect, it
should be noted that mice studies in which PCB 126 was used
as a reference compound were excluded from the database and
from further consideration because of other methodological
reasons (Haws et al., 2006).
Literature data also indicate that the PCB 126 REP for
enzyme induction in human cell systems, including primary
hepatocytes, breast cancer cell lines, and primary lymphocytes,
may be one or two orders of magnitude lower (van Duursen
et al., 2003; Zeiger et al., 2001). In addition, the apparent
binding affinity of 2,3,7,8-TCDD to the human AhR is
generally 1/10th that of the AhR of the more sensitive rodent
species, but significant variation among individual humans
occurs (Ema et al., 1994; Harper et al., 2002; Poland et al.,
1994; Ramadoss and Perdew, 2004; Roberts et al., 1990). It has
been suggested that on average, humans are among the more
dioxin-resistant species, but the human data set is too limited to
be conclusive (Harper et al., 2002; Okey et al., 2005). A study
with AhR-humanized mice may indicate lower responsiveness
toward toxic effects of 2,3,7,8-TCDD (Moriguchi et al., 2003).
Taken together, this information warrants more research into
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REP values in human systems to establish if the present TEFs
based on rodent studies are indeed also valid for humans.
Additivity is an important prerequisite of the TEF concept,
and this aspect was revisited in detail by the 2005 expert panel.
It was concluded that results from recent in vivo mixture
studies with dioxin-like compounds are consistent with addi-
tivity and support the TEF approach (Fattore et al., 2000; Gao
et al., 1999; Hamm et al., 2003; Walker et al., 2005). Gao et al.
(1999) studied the REP and additivity of 2,3,7,8-TCDD,
1,2,3,7,8-PeCDD, and 1,2,3,4,7,8-HxCDD in a rat ovulation
model; their results confirmed both parallel dose-response
curves and mixture additivity. Fattore et al. (2000) measured
hepatic vitamin A reduction in rats after subchronic dietary
exposure to a low-dose mixture containing 1,2,3,7,8-PeCDD,
2,3,4,7,8-PeCDF, and 1,2,3,6,7,8-HxCDF to test additivity. The
effects of this mixture showed that the predicted results based
on WHO 1998 TEFs were approximately twofold higher.
Hamm et al. (2003) studied a mixture of nine dioxins, furans,
and coplanar PCBs and looked at developmental reproductive
endpoints in rats, comparing results of the mixture to that of
2,3,7,8-TCDD alone. The results showed that the experimental
estimated TEQ was within a factor of two of that predicted
from the WHO 1998 TEFs. A mixture study from the National
Toxicology Program was also examined by the expert panel,
and again the results generally supported additivity and parallel
dose-response curves for complex and long-term neoplastic
and nonneoplastic endpoints (Walker et al., 2005).
Thus, results in these recent mixture studies could be
predicted rather well with the WHO 1998 TEFs, within a factor
of two or less. This degree of accuracy was somewhat
surprising in view of the complicated experimental situation
present in subchronic toxicity studies, where congener-specific
toxicodynamics and kinetics are intermingled and can in-
fluence the final outcome. In addition, the WHO 1998 TEFs
were derived from a range of REPs using different biological
models or endpoints and were therefore estimates with an order
of magnitude uncertainty (Van den Berg et al., 1998).
PROCESS USED TO DETERMINE TEF VALUES:
POINT ESTIMATES, EXPERT JUDGMENT, AND
PROBABILISTIC DISTRIBUTION
Both the WHO 1993 and 1997 TEF reevaluations used point
estimates derived by expert judgment from a wide range of
REPs (Ahlborg et al., 1994; Van den Berg et al., 1998). In the
2005 TEF reevaluation, it was decided by the expert panel to
use the REP database from Haws et al. (2006) for initial
assessment of a TEF value. This recently published database
and applied criteria were a refinement of the criteria and
database that were developed to support the two previous WHO
TEF reevaluations (Ahlborg et al., 1994; Van den Berg et al.,
1998). The criteria for inclusion or exclusion of an REP in this
database (Haws et al., 2006) were accepted by the expert panel.
These criteria can be summarized as follows:
 At least one test congener and a valid reference
compound must have been included in the study or the
reference compound must have been included in an identical
experiment from the same laboratory, but in another study.
 The endpoint must have been an established AhR-
mediated response known to be affected by both the test
congener and the reference compound.
 In the REP database, in vivo and in vitro studies were
separated.
 Repetitive endpoints (i.e., measures of the same bi-
ological response) were identified in all studies in the
database, and the most representative REP value was retained
for reevaluation of a TEF.
 Those studies that used only a single-dose level of either
the test and/or reference compound were filtered out of the
REP database and not used in the TEF reevaluation process.
 Results from non-peer–reviewed studies were not used in
reevaluating a TEF value and consequently did not contribute
to the distribution of REPs for individual congeners.
 REPs based on biological responses that were statistically
significant were included in the 2005 REP database and
contributed to the distribution of REPs for individual con-
geners used to reevaluate TEFs. However, when there was
a very limited data set for an individual congener, the panel
also considered biological responses that were not statistically
significant as part of the overall expert judgment in reevaluat-
ing a TEF value.
 REPs based on quantitative structure-activity relationship
studies were included in the REP database.
When using this database, the primary focus of the TEF
reevaluation was on in vivo studies (Haws et al., 2006). In vitro
studies were only used for support in those situations where no
or very few in vivo REP data were available. For in vitro REPs,
only established AhR-mediated responses were used to assign
REP values.
During the TEF reevaluation, the expert panel considered
using REP distributions available from the REP database
(Haws et al., 2006) when reevaluating a TEF value. However,
the REP distributions in this study are unweighted (Haws et al.,
2006), and it was decided that establishing a weighting criteria
for REPs generated in different types of studies (in vivo,
in vitro, chronic, acute, etc.) was not feasible at this meeting. In
addition, it was concluded that REP distributions for a specific
congener in this database could not be used to derive a TEF
value because a fixed percentile would have to be used as
a cutoff point. Such an approach would be like using a single
point estimate, but with lower biological or toxicological
relevance. This is because all types of in vivo studies (acute,
subchronic, etc.) and different endpoints have been combined,
and associated REP distributions are shown as a single box plot.
Thus, with only unweighted distributions of REPs available,
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a final expert judgment in the TEF reevaluation process
involving the type and quality of the study had preference
over the unweighted REP distributions (Haws et al., 2006).
Nevertheless, it was recognized by the expert panel that in
the future weighted REP distributions could be used for
derivation of TEF values, but establishing consensus values
for these REP weighting factors would require additional
expertise.
The WHO expert panel decided that a combination of these
unweighted REP distributions, expert judgment, and point
estimates would be used to reevaluate a TEF. Figure 1 shows
the unweighted distribution of in vivo and in vitro REPs and
WHO 1998 TEF values for PCDDs, PCDFs, non-ortho PCBs,
and mono-ortho PCBs (Haws et al., 2006). These unweighted
REP distributions were used to start the selection and decision
process for a TEF reevaluation. The 75th percentile of the
in vivo REP distribution for an individual congener was used as
an initial decision point to review the WHO 1998 TEF for that
congener. If the WHO 1998 TEF was below the 75th percentile
of the in vivo REP distribution, the data driving this TEF value
was extensively reevaluated. If the WHO 1998 TEF value was
above the 75th percentile, a quick review was done regarding
the decision made at the 1997 WHO meeting with respect to
those studies that had been driving the 1998 WHO TEF value.
In addition, results of new studies conducted after 1997 or old
information missed at the 1997 WHO meeting were evaluated
to determine if these would influence the WHO 1998 TEF
value for that congener. Based on the combined information,
a possible new TEF value was considered. Special attention
was also given to validity of WHO 1998 TEF values that were
near or higher than the 90th percentile, e.g., 1,2,3,7,8-PeCDF.
Thus, the above TEF reevaluation process provided a way both
to increase as well as to decrease a TEF value. Figure 2
illustrates the decision scheme used at the expert meeting for
the initial reevaluation process of the TEFs. For transparency,
the expert judgment process and rationale used by the expert
panel for a possible newly assigned WHO 2005 TEF value is
explained in the next paragraph. This is followed by subsequent
paragraphs devoted exclusively to each congener reevaluated.
As in previous WHO TEF consultations, it was decided by
the expert panel to use a stepwise scale for assigning TEFs
values. However, instead of assigning TEFs in the increments
used previously (0.01, 0.05, 0.1, etc.), it was decided to use half
order of magnitude increments on a logarithmic scale at 0.03,
0.1, 0.3, etc. As a result, all (non)revised 2005 WHO TEFs
were fitted on a logarithmic scale. This decision to assign TEFs
as half order of magnitude estimates may be useful in
describing, with statistical methods, the uncertainty of TEFs
in the future. Thus, as a default, all TEF values are assumed to
vary in uncertainty by at least one order of magnitude,
depending on the congener and its REP distribution. Conse-
quently, a TEF of 0.1 infers a degree of uncertainty bounded by
0.03 and 0.3. For a TEF value of 0.3, a degree of uncertainty
bounded by 0.1 and 1 was used. Thus, the TEF is a central value
with a degree of uncertainty assumed to be at least ± half a log,
which is one order of magnitude. However, it should be
realized that TEF assignments are usually within the 50th to
75th percentile of the REP distribution, with a general in-
clination toward the 75th percentile in order to be health
protective. However, the latter approach was also influenced by
the type and quality of study, e.g., single versus multiple dose,
that could not been discerned from the REP distributions shown
in Figure 1. This more conservative and health protective
approach practically means that for a TEF value the likelihood
of a half-log error too low is less than the likelihood of half
a log error too high. Due to the new ‘‘spacing’’ to express TEFs
on a half-log scale, it was also necessary in the final review
process to evaluate each individual TEF value for those
congeners for which there were no new data available.
WHO 2005 TEF VALUES
1,2,3,7,8-PeCDD
The WHO 1998 TEF was set at 1.0, which is above the 90th
percentile of the REP distribution of 12 in vivo studies. New
studies indicate an REP between 0.1 and 1.0 for this compound
(Fattore et al., 2000; Johnson et al., 2000; Simanainen et al.,
2002). The vitamin A and tumor promotion studies provide
REPs of 0.7 and 1 (Fattore et al., 2000; Waern et al., 1991).
Results from acute toxicity studies result in REPs closer to 0.5,
but, in general, REPs increase in subchronic toxicity studies
(Haws et al., 2006). Therefore, the consensus WHO 2005 TEF
value remained at 1.
1,2,3,4,7,8-HxCDD
The WHO 1998 TEF was set at 0.1, which is around the 80th
percentile of the REP distribution of five in vivo studies. One
new study determined REPs ranging from 0.04 to 0.12 (Gao
et al., 1999), while two other recent studies observed REPs
between 0.06 and 0.4 (Simanainen et al., 2002; Takagi et al.,
2003). Very little data indicate that the TEF value should be
changed to either 0.3 or 0.03. Therefore, it was decided to keep
the WHO 2005 TEF value at 0.1.
1,2,3,6,7,8-HxCDD
The WHO 1998 TEF was set at 0.1. No in vivo studies are
available for this HxCDD isomer. This TEF value is above the
75th percentile of the REP distribution of four in vitro studies
(Haws et al., 2006). A more recent in vitro study (Bols, 1997)
supports this TEF value, and therefore, no change for the WHO
2005 TEF was decided.
1,2,3,7,8,9-HxCDD
Similar to the above previous hexa-isomers, the WHO 1998
TEF was set at 0.1. It was noted that very little in vivo data are
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available with a recent study giving an REP of 0.029 (Takagi
et al., 2003). In addition, four in vitro studies produced REPs
up to 0.07 (Lipp et al., 1992; Schrenk et al., 1991), which is
above the 75th percentile of the distribution. The expert panel
considered decreasing the TEF value to 0.03 but decided that
there was not enough data to support such a change. In vitro
data were observed to be consistent between HxCDD isomers.
In view of the homology between the HxCDD isomers, it was
therefore decided to retain the old value of 0.1 as the WHO
2005 TEF value.
FIG. 1. Distribution of in vivo unweighted REP values in the REP2004 database. Reprinted with permission from (Haws et al., 2006).
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1,2,3,4,6,7,8-HpCDD
The WHO 1998 TEF was set at 0.01, which is at the 50th
percentile of the REP distribution range of four in vivo studies.
New studies again point toward an REP of 0.01 for this
congener (Simanainen et al., 2002; Viluksela et al., 1994,
1997a,b). An earlier tumor promotion study also indicated
a similar REP (Schrenk et al., 1994). It was also discussed
whether or not the available information from the important
studies mentioned above would be sufficient to increase the
TEF to 0.03, which is well above the 90th percentile of the REP
distribution. This suggestion was rejected by the expert panel.
It was decided to retain the WHO 2005 TEF value as 0.01.
Octachlorodibenzo-p-dioxin
TheWHO 1998 TEF was set at 0.0001, which is well outside
the 10th percentile of the range of in vivo and in vitro REP
values (Haws et al., 2006). At present, the only in vivo REPs
meeting the stringent conditions of the database (Haws et al.,
2006) are based on one study that was reported in two
different papers using different endpoints (Fattore et al.,
2000; Wermelinger et al., 1990). It was discussed whether or
not this TEF should be increased to bring it in line with the
results of the subchronic toxicity study (Fattore et al., 2000;
Wermelinger et al., 1990). The new in vivo REP data from
Fattore et al. (2000) were evaluated, and these would support
a TEF greater than 0.0001. One concern that was expressed
within the expert panel was that the animals used in a more
recent publication (Fattore et al., 2000) were the same animals
used in an earlier study (Wermelinger et al., 1990), and this
octachlorodibenzo-p-dioxin (OCDD) was reported to be con-
taminated with other more potent 2,3,7,8–substituted conge-
ners such as 2,3,4,7,8-PeCDF. Using the NTP data now
available for 2,3,4,7,8-PeCDF (Walker et al., 2005), it was
calculated that the reported contamination of 2.5 ppm (pg/lg)
2,3,4,7,8-PeCDF was not of toxicological relevance for the
results (Calculation of 2,3,4,7,8-PeCDF contamination in
OCDD Fattore et al. study [2000]. 2.5 ppm ¼ 2.5 pg/lg
OCDD. Highest OCDD dose 800 ppb ¼ 800 ng/g ¼ 0.8 lg/g
feed. At this dose level, the PeCDF dose must have been 2.5 pg
PeCDF/0.8 lg OCDD/g feed, which is equivalent with 2 pg
PeCDF/g feed. Assuming a rat of 200 g with 20 g feed per day,
the PeCDF dose must have been 40 pg PeCDF/200 g rat, which
is equivalent with 200 pg PeCDF/kg/day or 0.2 ng PeCDF/kg/
day. This dose is two orders of magnitude lower than the lowest
dose (20 ng PeCDF/kg/day) used in the National Toxicology
Program and well below the no observed effect level (NOEL)
of all endpoints that were looked at.). Overall, it was concluded
that there is very limited in vivo information available with only
one subchronic toxicity study (Fattore et al., 2000; Werme-
linger et al., 1990). The expert panel decided that the
information provided by both in vivo studies derived from
only one experiment did not provide a solid basis to increase
the TEF value for this compound to 0.001, but the combined
information from in vivo and in vitro data (Haws et al., 2006)
did justify a raise in TEF value. Therefore, it was decided to
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FIG. 2. Decision scheme used in the 2005 reevaluation of the 1998 WHO TEF values (Van den Berg et al., 1998) assigned to individual PCDD, PCDF, and
PCB congeners.
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increase the WHO 2005 TEF value to 0.0003. The expert panel
is aware of the implications that the increase in this WHO TEF
value for OCDD might have from a regulatory and risk
management point of view. However, with respect to the high
concentrations of OCDD in some environmental matrices,
a number of critical remarks regarding the inappropriate use of
the present WHO TEFs are made in the section on the use of
TEQ for abiotic environmental matrices.
2,3,7,8-TCDF
The WHO 1998 TEF was set at 0.1. This value is at the 75th
percentile of the REP distribution of nine in vivo studies for this
compound (Haws et al., 2006). Only one new study has been
reported (Takagi et al., 2003), and an REP of 0.07 was found
for increased cleft palate formation, which is close to the TEF
of 0.1. Consequently, it was decided that the WHO 2005 TEF
should remain at 0.1.
1,2,3,7,8-PeCDF
The WHO 1998 TEF was set at 0.05, which is within the
50th and 75th percentile of the REP distribution of eight in vivo
studies. A new study by Fattore et al. (2000) found an REP of
0.01 for effects on hepatic vitamin A reduction, but a study by
Takagi et al. (2003) reported an REP of 0.045 for cleft palate.
The majority of the in vivo studies report an REP value below
0.1, but many relevant studies have REPs above 0.01.
Therefore, it was decided that the 2005 WHO TEF should
become 0.03.
2,3,4,7,8-PeCDF
The WHO 1998 TEF was set at 0.5, which is well above the
75th percentile of the REP distribution of eight in vivo studies.
Results from the long-term NTP study in female Sprague-
Dawley rats using many different endpoints are now available
to evaluate this earlier TEF value more closely. The REPs for
neoplastic endpoints from the NTP study (Walker et al., 2005)
are around 0.2–0.3, while nonneoplastic endpoints have REPs
that range from 0.7 to 1.1. An earlier subchronic study by
Pluess et al. (1998) pointed toward an REP of 0.4. More recent
studies using hepatic vitamin A reduction and immunological
effects as endpoints also point toward a TEF below 0.5 (Fattore
et al., 2000; Johnson et al., 2000). In view of this new
information, it was decided by consensus of the expert panel
to change the WHO 2005 TEF to 0.3.
1,2,3,4,7,8-HxCDF
The WHO 1998 TEF was set at 0.1, which is above the 75th
percentile of the REP distribution of six in vivo studies. No new
in vivo studies have been published since 1997, and in view of
the limited data, there was no reason to change this value. Thus,
the WHO 2005 TEF value remains 0.1.
1,2,3,6,7,8-HxCDF
The WHO 1998 TEF was also set at 0.1, and this value is
above the 75th percentile of the distribution of three in vivo
REPs, and when the results of in vitro and in vivo studies with
the PCDF are combined, REP values lie within the 50th and
75th percentile. A new study reported an REP of 0.03 for
hepatic vitamin A reduction (Fattore et al., 2000). However, the
animals analyzed were from an earlier study from which an
REP of 0.1 for subchronic toxicity was reported (Pluess et al.,
1998). In view of the limited number of studies available and the
fact that WHO 1998 TEFs of 0.1 for most HxCDFs were all
around the 50th to 75th percentile (Haws et al., 2006), the expert
panel decided not to discriminate between TEF values for these
congeners. As a result, the 2005 WHO TEF remains at 0.1.
1,2,3,7,8,9-HxCDF
The WHO 1998 TEF for this HxCDF was set at 0.1. There
are no in vivo results, and only two earlier in vitro studies for
this congener with REPs of 0.2 and 0.1 (Brown, 2001; Tysklind
et al., 1994) supporting the 0.1 TEF value similar to the other
HxCDFs. Consequently, the 2005 WHO TEF remains as 0.1.
2,3,4,6,7,8-HxCDF
The WHO 1998 TEF value is 0.1, and it is around the 50th
percentile of the REP distribution range of the combined in vivo
and five in vitro studies (Haws et al., 2006). Most in vitro studies
suggest a TEF value slightly above 0.1 (Bandiera et al., 1984;
Brown, 2001; Mason et al., 1987; Tysklind et al., 1994). There
is only one in vivo study for this hexa-isomer indicating REPs
for different endpoints ranging from 0.02 to 0.1. Given this
weak and limited REP database and approximate similarities in
responses for this and certain other HxCDFs, there was con-
sensus in the expert panel to retain the 2005 WHO TEF at 0.1.
1,2,3,4,6,7,8- and 1,2,3,4,7,8,9-HpCDFs
The WHO 1998 TEFs for both HpCDFs were set at 0.01.
Since 1997, there are no new in vivo studies published. Only
two in vitro studies have been published (Brown, 2001;
Tysklind et al., 1994) reporting REPs, respectively, of 0.02
and 0.3 for 1,2,3,4,6,7,8-HpCDF and 0.04 and 0.02 for
1,2,3,4,7,8,9-HpCDF. Although these in vitro results do suggest
a slightly higher TEF than 0.01, the expert panel thought that
there was too much uncertainty in this limited database to raise
the TEF. In addition, it was expected that in vivo, therewould be
low absorption of these HpCDFs from the gastrointestinal tract,
thereby reducing their relative potency below that of the in vitro
REPs. Based on these arguments, it was decided that the WHO
2005 TEFs would remain the same for both isomers, 0.01.
Octachlorodibenzofuran
The WHO 1998 TEF value of 0.0001 is within the 50th and
75th percentile of the REP distribution range of three in vivo
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studies, but when these data are combined with in vitro results,
it falls below the 50th percentile (Haws et al., 2006). The recent
study by Fattore et al. (2000) using the same animals as
Wermelinger et al. (1990) indicate an REP for octachlorodi-
benzofuran (OCDF) greater than 0.0001 based on hepatic
vitamin A reductions. Some earlier in vivo studies also indi-
cated an REP higher than the WHO 1998 TEF (DeVito et al.,
1998; van Birgelen et al., 1996a; Waern, 1995). As with
OCDD, there was originally concern among the expert panel
about impurities with 2,3,7,8-chlorine–substituted congeners
(Fattore et al., 2000; Wermelinger et al., 1990), but calculations
indicated that the reported contamination with 1,2,3,4,6,7,8-
HpCDF was of no toxicological concern. When the limited
number of in vivo and in vitro REPs (< 10) are reviewed, REPs
range from 43 106 to 0.0028 with a 50th percentile of 0.0007
(Haws et al., 2006). As with OCDD, the expert panel decided
that the limited in vivo information available would not warrant
a factor of 10 increase of the WHO 1998 TEF value, but
increasing the WHO 2005 TEF value to 0.0003 is appropriate
in view of some of the higher in vivo REPs reported. This
would also be in line with comparable REP values obtained in
a recent study including both OCDD and OCDF (Fattore et al.,
2000).
PCB 77
The WHO 1998 TEF value of 0.0001 is just below the 75th
percentile in a very nonhomogenous distribution of six in vivo
REPs. The available subchronic toxicity studies are all around
the 75th percentile (Chu et al., 1995; Hakansson et al., 1994).
Immunotoxicological studies with mice were given less weight
(Harper et al., 1995; Mayura et al., 1993) because these were
acute studies involving the ip route of exposure, and no
information on purity was provided. It was decided by the
expert panel that the subchronic study was still the most
representative (Chu et al., 1995). As a consequence, the WHO
2005 TEF value remained at 0.0001.
PCB 81
The WHO 1998 TEF value was 0.0001. PCB 81 has been
observed in wildlife and human milk (Kumar et al., 2001),
confirming the validity of inclusion of this PCB in the TEF
scheme. There are no new in vivo data for this PCB congener.
Older in vivo data were excluded because these involved
single-dose studies from which the expert panel believed that
no reliable REP value could be determined. Various in vitro
studies with human hepatoma HepG2 cells and monkey
hepatocytes indicate that PCB 81 is more potent than PCB
77 (Brown, 2001; Pang et al., 1999; van der Burght et al., 1999;
Zeiger et al., 2001). Based on the in vitro REP distribution, it is
noticeable that the WHO 1998 TEF is located at the very low
end of the REP distribution range (Haws et al., 2006). Thus,
based on the information that PCB 81 is more potent in vitro
and more persistent than PCB 77, the expert panel decided to
raise the WHO 2005 TEF value to 0.0003. However, the expert
panel expressed its low confidence in the PCB 81 REP database
because it lacks in vivo REP data.
PCB 126
TheWHO 1998 TEF was set at 0.1, which is at the median of
the REP distribution range of 20 in vivo studies. This 1998 TEF
value was mainly driven by the tumor promotion study with
this compound (Hemming et al., 1995). New in vivo studies
from the NTP covering many endpoints (Johnson et al., 2000;
Walker et al., 2005) support the TEF of 0.1. In rat studies, the
expert panel recognized the tight range of REPs for this
congener (Haws et al., 2006), which supports the use of PCB
126 as reference compound with a TEF of 0.1 when comparing
rat studies. Information from mice studies and some human in
vitro systems (especially for enzyme induction) suggest that the
REP for PCB 126 might be lower than 0.1 (Birnbaum and
DeVito, 1995; DeVito et al., 2000; Harper et al., 1993; van
Birgelen et al., 1996a; van Duursen et al., 2003; Zeiger et al.,
2001). Clearly, more information is necessary regarding this
issue. Although concern was expressed about interspecies
variability in REPs, the expert panel considered the present
information too limited to make a decision other than to retain
0.1 as the WHO 2005 TEF.
PCB 169
The WHO 1998 TEF was set at 0.01, which is below the
median in the REP distribution range of seven in vivo studies.
The 1998 TEF was mainly driven by a 4-week repeated dose
mouse study measuring enzyme induction and generating an
REP of less than 0.001 (DeVito et al., 1998). On the other hand,
REPs from several other in vivo studies ranged from less than
0.01 to 0.7 (Harper et al., 1993; Parkinson et al., 1981;
Yoshimura et al., 1979). Thus, large differences in REPs have
been observed for PCB 169 between both species and
endpoints. In view of the fact that the WHO 1998 TEF was
also below the median of the in vivo REP distribution (Haws
et al., 2006), the expert panel decided that it was appropriate to
raise the TEF between the 50th and 75th percentile (see Figure
1). Nevertheless, many single-dose studies were observed to
have significantly higher REPs (around 0.1) than those
observed in a 13-week study. In view of these significant
differences between single- and multiple-dose studies, the
expert panel judged that the WHO 2005 TEF for PCB 169 of
0.03 would be more appropriate than a potentially overly
conservative REP of 0.1.
Mono-Ortho–Substituted PCBs 105, 114, 118, 123, 156,
157, 167, and 189
The WHO 1998 TEF values for the mono-ortho PCBs
ranged from 0.00001 to 0.0005. A major issue with the REP
values for the different mono-ortho PCBs is that they span four
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to five orders of magnitude, depending on the congener. In
Figure 3, this wide variation in REPs is illustrated. Even if only
in vivo studies are considered, the 90% distribution range is
extremely large (see Figure 1). This great variation in REP
values was of serious concern to the expert panel. The panel
considers possible, inconsistent, and low level contamination
of the mono-ortho PCBs with more potent dioxin-like com-
pounds to play, at least in part, a role in causing this large
variation. De Vito (2003) found that less than 1% contamina-
tion of PCB 77 by PCB 126 significantly impacted the apparent
REP of PCB 77. Shortly before the WHO 2005 TEF reevalua-
tion meeting, two laboratories of panel members performed
a number of in vitro experiments in an attempt to elucidate the
possible impact of impurities on REPs for the mono-ortho
PCBs (Peters et al., 2006). This study showed that after being
purified on charcoal, the mono-ortho PCBs 105, 118, 156, and
167 did not cause AhR-mediated activation and CYP1A1
induction in two genetically modified rodent hepatoma CA-
FLUX cell lines at concentrations that would generally justify
an REP larger than 0.0001. Based on the combined informa-
tion, the expert panel expressed low confidence in the higher
REP values for certain mono-ortho PCBs. It was concluded
that the unusually wide variability of REP values for mono-
ortho PCBs can probably be explained by the occurrence of
impurities with 2,3,7,8-chlorine–substituted PCDDs and
PCDFs or PCB 126. As the occurrence of these impurities
clearly depends on the route of synthesis and the degree of
cleanup, it was not possible to make a general statement about
how it occurs in all cases. It was concluded that for future
studies with mono-ortho PCBs or any other weak AhR
agonists, a purity of > 99% is clearly not sufficient to establish
a reliable REP. The expert panel compiled Figure 3 to make
a decision on the TEF values of the mono-ortho PCBs,
acknowledging the impurity issue and that the earlier decision
scheme with  75th percentile (Fig. 2) was not appropriate. In
this case, the most environmentally relevant mono-ortho PCBs
are 105, 118, and 156, and it was decided to use the medians of
the REP distribution range of these PCB congeners as a guide.
This resulted in a recommended TEF of 0.00003 for these three
mono-ortho PCBs. A differentiation for all other remaining
mono-ortho PCBs was considered not feasible by the expert
panel due to the lack of sufficient experimental data. Conse-
quently, the recommended WHO 2005 TEF for all mono-ortho
PCBs is 0.00003.
OTHER COMPOUNDS DISCUSSED FOR POSSIBLE
INCLUSION IN THE TEF SCHEME
PCB 37
PCB 37 is commonly found in the environment (Hansen,
1998). It has also been detected in edible fish species at levels
comparable with PCB 77 and 81 (Sapozhnikova et al., 2004).
In seals, it has been measured in relatively high levels,
indicating possible bioaccumulative properties in the food
chain (Addison et al., 1999). It has also been found in human
milk (Hansen, 1998). In an in vitro study with the human
MCF-7 breast carcinoma and HepG2 hepatoma cell lines, no
induction of CYP1A1 or 1B1 could be found. However, PCB
37 was found to be a significant catalytic inhibitor of both CYP
activities (Pang et al., 1999). In view of the above information,
there is a clear need for more in vivo and in vitro information to
decide if this PCB needs to be included in the TEF scheme.
Polybrominated Dibenzo-p-Dioxins and Polybrominated
Dibenzofurans
Both in vitro and in vivo studies have shown that poly-
brominated dibenzo-p-dioxins (PBDDs) and polybrominated
dibenzofurans (PBDFs) have AhR agonist properties and cause
dioxin-like effects (Birnbaum et al., 2003; Mason et al., 1987).
Emerging data from Japan and the Baltic Sea indicate that
PBDDs and PBDFs can be found in sediment, mussels, and
higher trophic species like the cormorant (Choi et al., 2003;
Malmvarn et al., 2005; Takigami et al., 2005; Watanabe et al.,
2004). In addition, there is limited recent information showing
that these compounds are found in human milk and adipose
tissue at levels that can contribute significantly to the total
amount of TEQ (Choi et al., 2003; Kotz et al., 2005; Ohta et al.,
2005). It appears that environmental levels might be signifi-
cantly lower than those of the PCDDs, PCDFs, and PCBs
already in the TEF scheme. However, a better exposure
assessment especially with regard to humans is needed. If the
presence of PBDDs and PBDFs in human food as well as in
people is more extensively demonstrated, there would be a clear
FIG. 3. Distribution of REP values for the different mono-ortho PCBs
based on AhR-mediated effects.
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need for assigning TEFs to these compounds. At present, it is
unclear to what extent the ongoing use of brominated flame
retardants, especially polybrominated diphenylethers (PBDEs),
could lead to an increase in human and environmental exposure
to PBDDs and PBDFs. Therefore, it is recommended by the
expert panel to perform a more thorough exposure analysis for
humans. In addition, it was concluded that among all com-
pounds proposed in this paragraph for development of WHO
TEFs, the PBDDs and PBDFs should be given high priority.
More REP studies on PBDDs and PBDFs are urgently needed.
Mixed Halogenated Dibenzo-p-Dioxins and Mixed
Halogenated Dibenzofurans
Due to the extremely high number of congeners, analysis of
mixed halogenated dibenzo-p-dioxins (PXCDDs) and mixed
halogenated dibenzofurans (PXCDFs) is still a major problem.
Very little is known about the possible relevance of these
compounds for human exposure (Birnbaum et al., 2003). If the
mixed halogenated (bromine- and chlorine-substituted) dioxins
and dibenzofurans are indeed detected in humans and their
food, these should definitely be considered for inclusion in the
TEF scheme. Early in vitro studies suggest that these com-
pounds follow the same structure-activity rules as the PCDDs
and PCDFs (Behnisch et al., 2001; Mason et al., 1987; Weber
and Greim, 1997).
Hexachlorobenzene
It has been suggested that hexachlorobenzene (HCB) fulfills
the criteria for inclusion in the TEF concept (van Birgelen,
1998), although arguments for doing so have been criticized
(Pohl et al., 2001; Schwab, 1999; Vos, 2000). HCB has mixed
inducer properties in analogy with the mono-ortho PCBs.
Before inclusion in the TEF concept is considered, it should be
confirmed that highly purified HCB has indeed AhR agonistic
properties, as contamination of HCB with PCDDs and PCDFs
has been reported (Goldstein, 1979) (Analysis of HCB done for
the U.K. Medical Research Council indicated levels of 16,000
ng OCDD/g, 6000 ng OCDF/g, 1000 ng HpCDF/g, and 88 ng
TCDD/g in HCB of high chemical quality [M. Rose, personal
communication].). Thus, results from earlier HCB studies
could have an impurity problem similar to that observed for
the mono-ortho PCBs. Priority should thus be given to confirm
the compound’s dioxin-like properties using highly purified
HCB with measured absence of 2,3,7,8-chlorine–substituted
dioxins and dibenzofurans or dioxin-like PCBs.
Polychlorinated Naphthalenes and Polybrominated
Naphthalenes
Based on recent published data, there was agreement by the
expert panel that these compounds definitely should be
considered for inclusion in the TEF concept as polychlorinated
naphthalenes (PCNs) are actually reported in food and humans
(Domingo et al., 2003; Falandysz, 2003; Hayward, 1998; Lunden
and Noren, 1998; Weistrand and Noren, 1998; Williams et al.,
1993). Earlier in vivo studies demonstrated that PCNs and
polybrominated naphthalenes (PBNs) were able to induce
dioxin-like effects, such as cleft palate and hydronephrosis
(Birnbaum et al., 1983; McKinney and McConnell, 1982;
Miller and Birnbaum, 1986). Further arguments for inclusion
would be that multiple PCN and PBN congeners have distinct
in vitro AhR activities that show analogy with PCDDs and
PCDFs but are less potent (Behnisch et al., 2003; Blankenship
et al., 2000; Darnerud, 2003; Robertson et al., 1982, 1984;
Villeneuve et al., 2000). However, as with mono-ortho PCBs
and HCBs, the possible impurity issue should be addressed
thoroughly before inclusion in the TEF concept is decided.
Polybrominated Biphenyls
Certain polybrominated biphenyls (PBBs) have been re-
ported to be AhR active in both in vitro and in vivo experiments
(Darnerud, 2003; Robertson et al., 1982, 1984). It was noted by
the expert panel that some human background exposure to
PBBs is still occurring. However, human exposure data outside
the ‘‘Michigan episode’’ are surprisingly scarce. Recently, PBB
exposure has been reported in bird species at the top of the food
chain from Japan and Norway (Herzke et al., 2005; Lindberg
et al., 2004; Watanabe et al., 2004). This occurrence in top
predator wildlife species also stresses the need to further
identify present human background exposure to PBBs. Thus,
based on the AhR mechanism of action, inclusion of certain
PBB congeners in the TEF scheme is appropriate, but further
human exposure analysis should identify the possible relevance
of PBBs to the total TEQ.
Polybrominated Diphenylethers
The expert panel accepted that PBDEs by themselves do not
have AhR agonist properties and should not be included in the
TEF concept (Chen and Bunce, 2003; Peters et al., 2004;
Sanders et al., 2005). However, commercial mixtures of
PBDEs can contain PBDDs and PBDFs that express signifi-
cant AhR-mediated activities, such as CYP1A1 induction
(Birnbaum et al., 2003; Hakk and Letcher, 2003). The expert
panel had concerns about earlier results in the literature,
indicating that PBDEs cause AhR-mediated effects because
of the possible impurity issue similar to that described for the
mono-ortho PCBs. In addition, it was also recognized that
photochemical and combustion processes of PBDEs can also
produce PBDDs and PBDFs. In conclusion, it was recom-
mended that TEFs should not be assigned for PBDEs.
‘‘NON-DIOXIN–LIKE’’ AHR LIGANDS AND
THE TEF CONCEPT
The AhR can bind and be activated by a structurally diverse
range of synthetic and naturally occurring chemicals (Denison
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and Heath-Pagliuso, 1998; Heath-Pagliuso et al., 1998; Jeuken
et al., 2003; Nagy et al., 2002). These chemicals are widely
distributed in dietary vegetables, fruits, teas, and dietary herbal
supplements sometimes at relatively high concentrations
(Amakura et al., 2002; Berhow et al., 1998; Formica and
Regelson, 1995; Herzog et al., 1993a,b; Jeuken et al., 2003).
The ability of metabolically labile phytochemicals to induce or
inhibit induction of CYP1A1-dependent activities by 2,3,7,8-
TCDD in cell culture model systems have been reported by
numerous laboratories (Amakura et al., 2002; Jeuken et al.,
2003; Williams et al., 1993; Zhang et al., 2003). However, the
majority of toxicity studies demonstrated that these naturally
occurring AhR agonists fail to produce AhR-dependent
toxicity (Leibelt et al., 2003; Pohjanvirta et al., 2002), although
some developmental dioxin-like effects have been reported for
indole-3-carbinol (I3C) (Wilker et al., 1996). In addition,
naturally occurring AhR ligands, such as I3C and diindoly-
methane, have been reported to inhibit 2,3,7,8-TCDD–de-
pendent in vivo induction of CYP1A1 and immunotoxicity
(Chen et al., 1995, 1996).
The ability of some non-dioxin–like PCBs and PCDFs to
inhibit 2,3,7,8-TCDD–induced CYP1A1 activity and immuno-
toxicity in C57BL/6J mice has also been reported (Bannister
and Safe, 1987; Biegel et al., 1989; Chen and Bunce, 2004;
Crofton et al., 2005; Davis and Safe, 1988; Loeffler and
Peterson, 1999; Morrissey et al., 1992; Smialowicz et al.,
1997), whereas other studies have shown synergistic effects on
dioxin toxicity of non-dioxin–like compounds, e.g., thyroid
hormones, porphyrins, reproductive toxicity, and immunotox-
icity (Bannister and Safe, 1987; Birnbaum et al., 1986; Crofton
et al., 2005; Loeffler and Peterson, 1999; van Birgelen et al.,
1996b).
The above studies provide evidence that non-dioxin–like
compounds that are weak AhR agonists can modulate the
overall toxic potency of 2,3,7,8-TCDD and related compounds.
If occurring under natural background situations, these inter-
actions might impact the magnitude and overall toxic effects
produced by a defined amount of TEQ (i.e., from intake or
present in the body) but not impact the determination of
individual REP or TEF values for dioxin-like chemicals. The
potential impact of these non-dioxin–like natural compounds
on the risk of toxicity posed by exposure to a particular level of
TEQs should be further investigated.
THE USE OF TEQ FOR ABIOTIC ENVIRONMENTAL
MATRICES
Concurrent with the development of the TEF and TEQ
approach has been its application to environmental matrices
such as soil, sediment, industrial wastes, soot, fly ash from
municipal incinerators, waste water effluents, etc. As such, the
TEQ approach has been and continues to be used to give
a single value to complex environmental matrices (Barnes,
1991; Barnes et al., 1991), usually without taking into
consideration whether this is actually a risk-based number.
The expert panel emphasized that correct application of the
present TEF scheme (see Table 1) and TEQ methodology in
human risk assessment is only intended for estimating exposure
to dioxin-like chemicals from consumption of food products,
breast milk, etc. This limitation is derived from the fact that
those REP studies that have been considered most relevant for
the determination of the present TEFs are largely based on oral
intake studies, often through the diet. In fact, experimental
toxicological studies using abiotic matrices with dioxin-like
compounds that would allow for the determination of environ-
mental matrice-based REPs (e.g., soil or sediment) are almost
nonexistent. Furthermore, the issue of matrix-specific bio-
availability of these chemicals from abiotic environmental
samples leads to a high degree of uncertainty for risk
assessment as this is largely dependent upon the organic
carbon content and age of the particles. For example, direct
TABLE 1
Summary of WHO 1998 and WHO 2005 TEF Values
Compound WHO 1998 TEF WHO 2005 TEF
Chlorinated dibenzo-p-dioxins
2,3,7,8-TCDD 1 1
1,2,3,7,8-PeCDD 1 1
1,2,3,4,7,8-HxCDD 0.1 0.1
1,2,3,6,7,8-HxCDD 0.1 0.1
1,2,3,7,8,9-HxCDD 0.1 0.1
1,2,3,4,6,7,8-HpCDD 0.01 0.01
OCDD 0.0001 0.0003
Chlorinated dibenzofurans
2,3,7,8-TCDF 0.1 0.1
1,2,3,7,8-PeCDF 0.05 0.03
2,3,4,7,8-PeCDF 0.5 0.3
1,2,3,4,7,8-HxCDF 0.1 0.1
1,2,3,6,7,8-HxCDF 0.1 0.1
1,2,3,7,8,9-HxCDF 0.1 0.1
2,3,4,6,7,8-HxCDF 0.1 0.1
1,2,3,4,6,7,8-HpCDF 0.01 0.01
1,2,3,4,7,8,9-HpCDF 0.01 0.01
OCDF 0.0001 0.0003
Non-ortho–substituted PCBs
3,3#,4,4#-tetraCB (PCB 77) 0.0001 0.0001
3,4,4#,5-tetraCB (PCB 81) 0.0001 0.0003
3,3#,4,4#,5-pentaCB (PCB 126) 0.1 0.1
3,3#,4,4#,5,5#-hexaCB (PCB 169) 0.01 0.03
Mono-ortho–substituted PCBs
2,3,3#,4,4#-pentaCB (PCB 105) 0.0001 0.00003
2,3,4,4#,5-pentaCB (PCB 114) 0.0005 0.00003
2,3#,4,4#,5-pentaCB (PCB 118) 0.0001 0.00003
2#,3,4,4#,5-pentaCB (PCB 123) 0.0001 0.00003
2,3,3#,4,4#,5-hexaCB (PCB 156) 0.0005 0.00003
2,3,3#,4,4#,5#-hexaCB (PCB 157) 0.0005 0.00003
2,3#,4,4#,5,5#-hexaCB (PCB 167) 0.00001 0.00003
2,3,3#,4,4#,5,5#-heptaCB (PCB 189) 0.0001 0.00003
Bold values indicate a change in TEF value.
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application of these WHO TEFs for assessment of OCDD or
OCDF present in soil, sediment, or fly ash would lead to
inaccurate assessment of the potential toxic potency of the
matrix. This derives primarily from the fact that the highly
hydrophobic PCDDs and PCDFs bind strongly to particles
thereby significantly reducing their bioavailability for living
organisms (Van den Berg et al., 1994). As a result, application
of these WHO TEFs for calculating the TEQ, e.g., OCDD and
OCDF, in abiotic environmental matrices has limited toxico-
logical relevance and use for risk assessment unless the aspect
of reduced bioavailability is taken into consideration. Never-
theless, the expert panel recognized that it is now common
practice to use the TEQ and associated TEFs directly to
characterize and compare contamination by dioxin-like chem-
icals of abiotic environmental samples and is even codified in
national and international legislation, e.g., the Stockholm
Convention on Persistent Organic Pollutants.
In relation to this use of the TEQ, it should be emphasized
that while these values by themselves do not have any
toxicological implications or direct use in risk assessment,
they can be a useful tool to compare concentrations within
similar abiotic matrices and serve a prioritization function.
Accordingly, it is recommended that when a human risk
assessment is to be done from abiotic matrices, factors such
as fate, transport, and bioavailibility from each matrix be
specifically considered before a final estimate of the toxico-
logical relevant TEQ is made. If a human risk assessment is
done for abiotic matrices, the expert panel recognized that it
would be preferable to use congener-specific equations
throughout the whole model rather than base it on total TEQ
in an abiotic matrix.
FUTURE RECOMMENDATIONS FOR DETERMINATION
OF TEF VALUES
Previous WHO TEF reevaluations have used expert judg-
ment and point estimates to establish congener-specific TEF
values. In addition, the 1997 expert meeting indicated that TEF
values were order of magnitude estimates (Van den Berg et al.,
1998). This statement was given irrespective of the type of
congener, even though large differences are present in the REP
studies of individual compounds (Haws et al., 2006). When
using point estimates and expert judgment, an advantage is that
selection of a TEF can be made from those studies which are
most relevant for human exposure (e.g., in vivo long term or
subchronic). A disadvantage is that such an approach does not
describe the range of REPs and may reflect a bias in judgment
within the expert panel.
Recently, several authors have published papers in which
they advocated the use of a probabilistic approach to determine
TEFs (Finley et al., 2003; Haws et al., 2006). In using such an
approach, there is a clear advantage because it will better
describe the level of uncertainty present in a TEF value. The
distribution of REPs can be expressed in terms of minimum and
maximum values combined with percentiles at different levels
(e.g., 25th and 75th percentiles). A disadvantage could be that
such an approach lumps all data together and gives similar
weight to all types of studies. In part, this problem could be
avoided by separating in vitro from in vivo REPs (Haws et al.,
2006).
However, if probabilistic approaches for setting a future TEF
are used, it is essential that weighting factors be applied to
REPs that are determined from different types of studies. These
weighted REP values could then be used to determine weighted
REP distributions in the risk assessment process. Clearly,
unweighted REP distribution ranges that bracket the TEFs
incorporate biological and toxicological uncertainty. For this
reason, in the WHO 2005 TEF reevaluation, unweighted REP
distribution ranges, expert judgment, and point estimates were
used in combination to assign TEFs. The sole use of
a probabilistic approach to determine TEF values also includes
other decision points, such as establishing a range instead of
a point estimate for the TEF value. However, the use of a TEF
range might cause problems for regulatory authorities and
international harmonization of TEF values because one or
more TEF values could then be selected for risk assessment
calculations. This might easily lead to different TEFs being
used by different countries depending on the level of conser-
vatism used in the risk management process by national
authorities. In this respect, the choice, e.g., of a 50th, 75th, or
95th percentile of the REP distribution range to assign a TEF is
a risk management decision.
Similar to the use of WHO 2005 TEFs and TEQ with abiotic
matrices, the application of these values to human tissue
samples must be carried out with caution. This is because the
present WHO TEF concept is, by default, primarily designed
for intake situations. There is emerging evidence suggesting
that the REP of certain dioxin-like compounds may differ when
the REP is determined based on administered dose versus tissue
concentration (Chen et al., 2001; DeVito et al., 2000; Hamm
et al., 2003). As a result, the use of systemic TEFs and TEQ has
been suggested as an additional approach to the present WHO
TEFs. From a biological and toxicological point of view, the
development and use of systemic TEFs is recommended, but
the expert panel was of the opinion that at present there is
insufficient data to allow the development of systemic TEFs. If
systemic TEFs would be developed in the future, TEF values
based on blood lipid concentration might be the preferred
choice. However, the use of intake TEFs from food is a valid
approach for estimation of human body burdens since many of
the concerns with issues of fate and transport when dealing
with abiotic matrices do not exist and many of the pharmaco-
kinetic issues are already (partially) dealt with during bio-
accumulation and biomagnification up the food chain.
With respect to the use of systemic TEFs, it would also be
useful to determine if in vitro–derived TEFs can potentially be
used as surrogates for systemic TEFs derived from in vivo
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studies. If such a relationship does exist, this would allow
a better use of the vast amount of in vitro data that has been
obtained for dioxin-like compounds over the last few decades.
In view of their direct biological relevance to humans, the
expert panel proposed that systemic or body burden TEFs for
humans should be developed in the near future. These body
burden/systemic TEFs would allow a more accurate quantita-
tive human dose-response assessment. However, it was also
concluded by the expert panel that such systemic TEFs should
be used in the future along with the 2005 WHO TEFs derived
for ingestion situations as both types of TEFs have different
valid applications. The TEQ based on intake TEFs can be used
to monitor intervention programs, while systemic or body
burden TEFs would be more applicable for biomonitoring
systemic levels of dioxin-like chemicals in humans. In
addition, body burden TEFs can also be used as the dose
metric for interspecies extrapolation. At present, the WHO
2005 TEFs that are based on intake can be applied for
characterization of exposure to dioxin-like chemicals in human
blood or tissues and comparisons across populations, but these
derived TEQ values have certain caveats from a risk assess-
ment point of view.
CONCLUSIONS
Additivity, an important prerequisite of the TEF concept was
found to be consistent with results from recent in vivo mixture
studies (Fattore et al., 2000; Gao et al., 1999;Hamm et al., 2003;
Walker et al., 2005). These studies showed thatWHO 1998 TEF
values predicted mixture toxicity within a factor two or less.
Such accuracy is almost surprising in view of the fact that TEFs
are derived from a range of REPs using different biological
models or endpoints and are considered estimates with an order
of magnitude uncertainty (Van den Berg et al., 1998).
The expert panel recognized that there are studies providing
evidence that non-dioxin–like AhR agonists and antagonists
are able to increase or decrease the toxicity of 2,3,7,8-TCDD
and related compounds. Accordingly, their possible effect on
the overall accuracy of the estimated magnitude of the TEQ
needs to be investigated further, but it does not impact the
experimental determination of individual REPs or TEFs.
For this TEF reevaluation process, the expert panel made
extensive use of the refined TEF database that was recently
published by Haws et al. (2006). Decisions about a TEF value
were based on a combination of unweighted REP distributions,
expert judgment, and point estimates. The use of solely
unweighted REP distributions to set a TEF value was rejected
because a specific percentile would have to be used as a cutoff,
which could equally well be considered as a point estimate.
However, such a percentile would have a lower biological or
toxicological relevance than that obtained by expert judgment.
Previous TEFs were assigned in increments of 0.01, 0.05,
0.1, etc., but for this reevaluation, it was decided to use half
order of magnitude increments on a logarithmic scale at 0.03,
0.1, 0.3, etc. This should be more useful in describing, with
statistical methods, the uncertainty of TEFs in the future. In
Table 1, the WHO 1998 and 2005 TEF values are summarized.
Figure 4 gives some indication of the quantitative impact of
the 2005 changes on WHO TEF values in some selected biotic
samples. The changes are shown as the ratio between the 2005
and 1998 WHO TEF values. In general, it can be concluded
that the changes in 2005 values have a limited impact on the
total TEQ of these samples with an overall decrease in TEQ
FIG. 4. Percent reduction in total TEQ levels calculated for the same biotic samples when 2005 TEFs rather than 1998 TEFs are used. For each biotic sample
shown, the height of the bar is the percent that the total TEQ level determined usingWHO 2005 TEFs is of the total TEQ level determined using WHO 1998 TEFs.
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ranging between 10 and 25%. The exception being the chicken
where the decrease of the TEF for 2,3,4,7,8-PeCDF (from 0.5
to 0.3) and of lower TEFs for the mono-ortho PCBs resulted in
an almost 50% decrease of total TEQ. In view of this average
impact of 10–25%, it should be realized that many duplicate
GC-MS analyses for these compounds also have an uncertainty
that can fall in the range of 10–25%.
Several groups of compounds were identified for possible
future inclusion in the TEF/TEQ concept. Based on mechanis-
tic considerations, PCB 37, PBDDs, PBDFs, PXCDDs,
PXCDFs, PCNs, PBNs, and PBBs undoubtedly belong in the
TEF concept. However, for most, if not all, of these compounds
there is a distinct lack of human exposure data. Therefore,
preliminary exposure assessments should be done in the near
future to indicate if these compounds are relevant for humans
with respect to TEQ dietary intake. In addition, HCB could be
a possible candidate for inclusion in the TEF/TEQ concept but
only if it is unequivocally shown that impurities have not been
the cause of earlier dioxin-like effects observed in experimental
models. With respect to PBDEs, it was concluded that there is
no reason for their inclusion in the TEF/TEQ concept.
Concern is expressed about the application of the TEF/TEQ
approach to abiotic environmental matrices, such as soil,
sediment, etc. The present TEF scheme (see Table 1) and
TEQ methodology are primarily meant for estimating exposure
via dietary intake situations because present TEFs are based
largely on oral uptake studies often through diet. Application of
these ‘‘intake or ingestion’’ TEFs for calculating the TEQ in
abiotic environmental matrices has limited toxicological
relevance and use for risk assessment, unless the aspect of
reduced bioavailability and environmental fate and transport of
the various dioxin-like compounds are taken into account. If
human risk assessment is done for abiotic matrices, it is
recommended that congener-specific equations be used
throughout the whole model, instead of using a total TEQ
basis, because fate and transport properties differ widely
between congeners.
A number of future approaches to determine alternative or
additional TEFs were identified. The use of a probabilistic
methodology to determine TEFs has the advantage that it better
describes the level of uncertainty in a TEF. The disadvantage
could be that this approach lumps data together and gives
similar weight to all studies, a problem that can only partly be
avoided by separating in vitro from in vivo REPs. In addition,
the sole use of a probabilistic approach includes other decision
points, e.g., establishing a range of values from which one or
more TEF values could be selected for risk assessment. Clearly,
such an approach might cause problems for regulatory
authorities and international harmonization of TEFs. Further-
more, choosing a specific percentile (e.g., 50th, 75th, or 95th)
would, in fact, not be far different from using a point estimate.
The use of the present TEF values with body burden matrices
as blood and adipose tissue have certain caveats from a risk
assessment point of view as they were determined from intake
situations. There is emerging experimental evidence which
suggests that some REPs may differ when based on adminis-
tered dose versus tissue concentration. The development and
use of systemic TEFs and TEQ are recommended as an
additional approach to the present TEF concept, but at present,
there are insufficient data to develop these systemic TEFs.
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